Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5635013 | 0.84 | ALDH1A1 (0.39) | ALDH1A1ALOX15TSHR | |
| SCHEMBL20267103 | 0.80 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHR | |
| SCHEMBL30861998 | 0.80 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHR | |
| SCHEMBL30166648 | 0.80 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHR | |
| SCHEMBL12599932 | 0.80 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHR | |
| SCHEMBL10620477 | 0.79 | — | — | |
| SCHEMBL24663882 | 0.76 | ALDH1A1 (0.32) | ALDH1A1ALOX15TSHR | |
| SCHEMBL6238742 | 0.76 | ALDH1A1 (0.32) | ALDH1A1ALOX15TSHR | |
| SCHEMBL30427115 | 0.76 | ALDH1A1 (0.32) | ALDH1A1ALOX15TSHR | |
| SCHEMBL2088817 | 0.74 | KEAP1 (0.32) | ALDH1A1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055358-A | GPR65 small molecule regulator and preparation method and application thereof | 四川大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4635949-A1 | SUBSTITUTED TETRAHYDROCYCLOPENTYL[C]PYRROLE DERIVATIVE, PREPARATION METHOD, INTERMEDIATE AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2025-10-22 | — | — | EP | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-20250223267-A1 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-119841847-A | Cyclic 2-amino-3-cyanothiophenes and derivatives thereof for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-12234211-B2 | Cycloolefin substituted heteroaromatic compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-02-25 | — | — | US | disclosed |
| WO-2025016899-A1 | SPIROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-23 | — | — | WO | disclosed |
| US-20250002504-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM RCV GMBH & CO. KG (AT) | 2025-01-02 | — | — | US | disclosed |
| EP-4471034-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLE METHYL KETONE DERIVATIVE AND APPLICATION THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-20240376081-A1 | POLYMORPH AND APPLICATION OF PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| WO-2007049041-A1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2006123113-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | WO | disclosed |
| EP-0499930-B1 | Process for the preparation of 5-fluoropyrimidines | BAYER AG (DE) | 1998-07-01 | — | — | EP | disclosed |
| US-5145961-A | PROCESS FOR THE PREPARATION OF 5-FLUOROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-09-08 | — | — | US | disclosed |
| EP-0499930-A1 | Process for the preparation of 5-fluoropyrimidines | BAYER AG (DE) | 1992-08-26 | — | — | EP | disclosed |
| US-4716229-A | New pyrimidines and a process for the preparation of pyrimidines | BAYER AKTIENGESELLSCHAFT (DE) | 1987-12-29 | — | — | US | disclosed |
| EP-0133663-B1 | PYRIMIDINES AND A PROCESS FOR THE PREPARATION OF PYRIMIDINES | BAYER AG (DE) | 1987-04-08 | — | — | EP | disclosed |
| EP-0069703-B1 | REACTIVE DYESTUFFS, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1986-04-23 | — | — | EP | disclosed |
| EP-0133663-A1 | Pyrimidines and a process for the preparation of pyrimidines | BAYER AG (DE) | 1985-03-06 | — | — | EP | disclosed |
| EP-0069703-A2 | Reactive dyestuffs, their preparation and their use | CIBA-GEIGY AG (CH) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002504-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | ALDH1A1 1320/4885ALOX15 4386/4885TSHR 1257/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | ALDH1A1 3132/4885ALOX15 719/4885TSHR 344/4885 |
| US-20250223267-A1 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | CYP4F11, CYP11B1, CYP11B2 | ALDH1A1 1756/4885ALOX15 1735/4885TSHR 980/4885 |
| US-12234211-B2 | Cycloolefin substituted heteroaromatic compounds and their use | CYP4F11, CYP11B1, CYP11B2 | ALDH1A1 1756/4885ALOX15 1735/4885TSHR 980/4885 |
| US-20240376081-A1 | POLYMORPH AND APPLICATION OF PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ADORA2B, ADORA2A, ADORA3 | ALDH1A1 648/4885ALOX15 2597/4885TSHR 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.